Optimized anti-CD3 arm in the generation of t-cell bispecific antibodies for immunotherapy
AssigneeShandong Boan Biotechnology Co., Ltd.
InventorsAvanish Varshney, Li Zhou, Irene Schneider
Life of this patent
Estimating the term…
Loading patent…
AssigneeShandong Boan Biotechnology Co., Ltd.
InventorsAvanish Varshney, Li Zhou, Irene Schneider
Estimating the term…
The present invention provides novel CD3 antigen binding fragments with particularly advantageous properties such as producibility, stability, binding affinity, biological activity, specific targeting of certain T cells, targeting efficiency, remaining tumor cell killing and reduced toxicity. The present invention also provides bispecific antigen binding molecules for activating T cells. In addition, the invention further provides methods of treating cancer in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising the above said bispecific antigen binding molecules.
A CD3 antigen binding fragment, comprising a heavy chain variable region and a light chain variable region, wherein:
Dependencies are inferred from the claim text.